ATYR SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces that aTyr Pharma Investors Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. related to misleading statements about the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [3][6]. Group 1: Legal Action and Investor Rights - Investors who purchased aTyr securities between January 16, 2025, and September 12, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [2][3]. - A federal securities class action has been filed against aTyr, with a deadline of December 8, 2025, for investors to seek the role of lead plaintiff [3][8]. Group 2: Allegations Against aTyr Pharma - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements regarding Efzofitimod's efficacy, particularly its ability to allow patients to taper off steroids completely [6]. - In the EFZO-FIT study, efzofitimod showed no significant change in mean daily oral corticosteroid (OCS) dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [7]. - The study reported that complete steroid withdrawal was achieved in 52.6% of patients treated with efzofitimod versus 40.2% on placebo [7]. Group 3: Market Impact - Following the release of the study results, aTyr's stock price plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [7].